Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Paratek Pharmaceuticals Inc    PRTK

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
03/20/2017 03/21/2017 03/22/2017 03/23/2017 03/24/2017 Date
16.4(c) 15.3(c) 15.55(c) 15.75(c) 15.85(c) Last
597 860 826 423 501 937 357 138 407 266 Volume
-0.91% -6.71% +1.63% +1.29% +0.63% Change
More quotes
Financials ($)
Sales 2017 2,62 M
EBIT 2017 -109 M
Net income 2017 -111 M
Finance 2017 8,93 M
Yield 2017 -
Sales 2018 20,6 M
EBIT 2018 -85,0 M
Net income 2018 -78,2 M
Finance 2018 1,87 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 158x
EV / Sales2018 20,5x
Capitalization 423 M
More Financials
Company
Paratek Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon its expertise in novel tetracycline chemistry.Its products include Omadacycline and Sarecycline.The company was founded in February 2001 and is... 
More about the company
Surperformance© ratings of Paratek Pharmaceuticals In
Trading Rating : Investor Rating :
More Ratings
Latest news on PARATEK PHARMACEUTICALS IN
03/24 PARATEK PHARMACEUTICALS : Reports Full Year and Fourth Quarter 2016 Financial Re..
03/24 Paratek Pharmaceuticals Opens New Office in King of Prussia
03/09 PARATEK PHARMACEUTICALS : Reports Summarize Clinical Pharmacology Study Results ..
03/02 PARATEK PHARMACEUTICALS : reports 4Q loss
03/02 PARATEK PHARMACEUTICALS : to Report Fourth Quarter and Full Year 2016 Financial ..
03/02 Paratek Pharmaceuticals, Inc. Reports Full Year and Fourth Quarter 2016 Finan..
03/02 PARATEK PHARMACEUTICALS : Management's Discussion and Analysis of Financial Cond..
02/22 PARATEK PHARMACEUTICALS : to Present at LEERINK Partners 6th Annual Global Healt..
02/22 Paratek Pharmaceuticals to Report Fourth Quarter and Full Year 2016 Financial..
02/11 PARATEK PHARMACEUTICALS : U.S. Patents Awarded to Inventors in Pennsylvania (Feb..
More news
Sector news : Bio Therapeutic Drugs
03/18DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 3rd Update
03/17DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 2nd Update
03/17DJAMGEN : Money-Back Guarantee
03/17DJAmgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- Update
03/17DJAmgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke
More sector news : Bio Therapeutic Drugs
Latest Tweets
03/24Paratek Pharmaceuticals Opens New Office in King of Prussia  
03/21Upcoming Events: Alder's Migraine Test, Paratek's Antibiotic $TEVA $PRTK $AMG.. 
03/21Upcoming Events: Alder's Migraine Test, Paratek's Antibiotic  
03/15Love the tight bull flag on this $PRTK just needs some volume 
03/13Paratek's Omadacycline Could Be A Game-Changer In Antibiotics  
More tweets
Qtime:11
News from SeekingAlpha
03/21 UPCOMING EVENTS : Alder's Migraine Test, Paratek's Antibiotic
03/13 Paratek's Omadacycline Could Be A Game-Changer In Antibiotics
03/12 PRO WEEKLY DIGEST : Investing With A Margin Of Safety With Brian Langis
03/06 BIOTECH FORUM DAILY DIGEST : Biotech Closes Above Resistance Levels. Icahn Getti..
03/02 Paratek Pharmaceuticals, Inc. 2016 Q4 - Results - Earnings Call Slides
Advertisement
Chart PARATEK PHARMACEUTICALS IN
Duration : Period :
Paratek Pharmaceuticals In Technical Analysis Chart | PRTK | US6993743029 | 4-Traders
Full-screen chart
Technical analysis trends PARATEK PHARMACEU...
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Average target price 38,4 $
Spread / Average Target 142%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Michael F. Bigham Chairman & Chief Executive Officer
Evan Loh President, COO, Director & CMO
Douglas W. Pagán CFO & Principal Accounting Officer
Thomas John Dietz Independent Director
Richard J. Lim Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
PARATEK PHARMACEUTICAL..2.92%423
AMGEN, INC.13.36%122 060
CELGENE CORPORATION6.59%95 986
GILEAD SCIENCES, INC.-5.73%88 240
REGENERON PHARMACEUTIC..1.61%39 568
ACTELION LTD24.44%29 804
More Results